TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8985794

Group type: EXPERIMENTAL
Intervention: Arm exercise at 30 Watts
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Leg exercise at 30 Watts
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Peak arm exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Peak leg exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (10 age-matched healthy subjects)
Number of subjects: 20
Study: 1615479

Group type: EXPERIMENTAL
Intervention: Lomoparan (Org 10172) 750 anti-factor Xa units, s.c., b.i.d. for 10 days
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Lomoparan (Org 10172)
Number of subjects: 197
Study: 6333182

Group type: COMPARATOR
Intervention: Epidermal growth factor, applied topically four times a day on the day of surgery and twice a day for two days thereafter.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Epidermal growth factor, applied topically at half concentration eight times a day for four days beginning the day before surgery.
Number of subjects: 2
Study: 31132578

Group type: EXPERIMENTAL
Intervention: Higher Sleep Regularity Index (SRI)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Phase angle
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Sleep onset time
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: SRI
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Total sleep time
Number of subjects: 170
Study: 29045997

Group type: EXPERIMENTAL
Intervention: CS and BIS monitoring
Number of subjects: 50

Group type: COMPARATOR
Intervention: CS alone
Number of subjects: 50
Study: 26092285

Group type: EXPERIMENTAL
Intervention: Internet-based headache diary (i-diary)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Paper diary (p-diary)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Both diary types
Number of subjects: 488
Study: 25301457

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 348689

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) in patients with MMRS <10
Number of subjects: 348689

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) in patients with MMRS ≥20
Number of subjects: 348689
Study: 22469850

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate and glucosamine hydrochloride (combination therapy)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (alone)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Glucosamine hydrochloride (alone)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 20502471

Group type: EXPERIMENTAL
Intervention: Family dietary coaching
Number of subjects: 2026

Group type: EXPERIMENTAL
Intervention: Targeting dietary changes
Number of subjects: 2026
Study: 18595980

Group type: COMPARATOR
Intervention: Synbiotics (4 probiotic species: Lactobacillus rhamnosus GG and LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp shermanii) with 0.8 g of galactooligosaccharides, daily for 6 months after birth.
Number of subjects: 925

Group type: COMPARATOR
Intervention: Placebo, daily for 6 months after birth.
Number of subjects: 925

Group type: COMPARATOR
Intervention: Synbiotics (4 probiotic species)
Number of subjects: 925

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 925
Study: 16149682

Group type: EXPERIMENTAL
Intervention: Combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (artificial tear)
Number of subjects: 28
Study: 12027232

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh)
Number of subjects: 24
Study: 10396665

Group type: EXPERIMENTAL
Intervention: Albunex 0.10 ml/kg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Albunex 0.15 ml/kg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Albunex 0.20 ml/kg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Albunex (all doses)
Number of subjects: 52
Study: 7601013

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study: 2123909

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone (2 mg/kg body weight per 10 min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous flecainide (2 mg/kg per 10 min)
Number of subjects: 50
Study: 7007057

Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30704531

Group type: EXPERIMENTAL
Intervention: READ anti-stigma training for medical students
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard teaching without READ training)
Number of subjects: 0
Study: 27647529

Group type: EXPERIMENTAL
Intervention: Decision aid (DA) provided via patient portal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision aid (DA)
Number of subjects: 0
Study: 25973934

Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) 200mg/kg/d
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 22841452

Group type: EXPERIMENTAL
Intervention: Xylazine (loading dose: 1mg/kg, CRI: 0.69mg/kg/h for 2h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Romifidine (loading dose: 80μg/kg, CRI: 30μg/kg/h for 2h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Romifidine vs Xylazine during CRI
Number of subjects: 9
Study: 21199965

Group type: EXPERIMENTAL
Intervention: Donepezil and antidepressant therapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Donepezil in mild cognitive impairment subgroup
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Normal cognition subgroup
Number of subjects: 130
Study: 19880458

Group type: EXPERIMENTAL
Intervention: Citalopram (initial treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent randomized trials (switching or augmenting treatments)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two vigorous medication trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complicated medication regimens
Number of subjects: 0
Study: 17079401

Group type: EXPERIMENTAL
Intervention: Preservation of the parietal layer of the ulnar bursa during open carpal tunnel decompression (57 patients)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Division of the ulnar bursa during open carpal tunnel decompression (61 patients)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Preservation of the ulnar bursa
Number of subjects: 118
Study: 14652833

Group type: EXPERIMENTAL
Intervention: Invasive therapy
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Supervised physical training
Number of subjects: 171

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 171
Study: 11708736

Group type: EXPERIMENTAL
Intervention: Attachment-oriented intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 9516030

Group type: EXPERIMENTAL
Intervention: Acetaminophen 0.5 g
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Acetaminophen 2 g
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7816383

Group type: EXPERIMENTAL
Intervention: Slope method
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Uptake index method
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Integral method
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Uptake index method (alpha/UI)SR
Number of subjects: 70

Group type: COMPARATOR
Intervention: Correlation of results
Number of subjects: 70
Study: 2971603

Group type: EXPERIMENTAL
Intervention: Norfloxacin (800 mg by mouth)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Spectinomycin (2 g intramuscularly)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 547

Group type: COMPARATOR
Intervention: Spectinomycin
Number of subjects: 547
Study: 31363961

Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Group (LIG)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 165
Study: 30119757

Group type: EXPERIMENTAL
Intervention: FLEX intervention (motivational interviewing and problem-solving skills training)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 258
Study: 26497696

Group type: EXPERIMENTAL
Intervention: Brief animated intervention delivered at the patients' bedside
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 70
Study: 24384584

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at 0.0125 μg(−1) kg(−1) min
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 22221571

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no HBO therapy)
Number of subjects: 0
Study: 20598107

Group type: EXPERIMENTAL
Intervention: IV iron sucrose (Venofer(®), 200 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral iron sulphate (Duroferon(®), 20×100 mg)
Number of subjects: 120
Study: 17269905

Group type: EXPERIMENTAL
Intervention: Community-based participatory research intervention through soccer leagues
Number of subjects: 0
Study: 16286670

Group type: EXPERIMENTAL
Intervention: Chronic L-carnitine L-tartrate supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acute L-carnitine L-tartrate supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11203580

Group type: COMPARATOR
Intervention: Polylactide (Guidor) resorbable membrane (GA sites)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination treatment of polylactide membrane plus polyglactin root‐lining mesh (Vicryl) and demineralized freeze‐dried bone allograft (DFDBA) (GVB sites)
Number of subjects: 12
Study: 9302150

Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg once daily
Number of subjects: 344

Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg twice daily
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily
Number of subjects: 344

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 344

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Fleroxacin and Ciprofloxacin
Number of subjects: 344
Study: 8365829

Group type: EXPERIMENTAL
Intervention: Albuterol (360 micrograms total dose, 90 micrograms per dose, 4 doses)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 21
Study: 3534585

Group type: EXPERIMENTAL
Intervention: LMF plus BCG
Number of subjects: 254

Group type: COMPARATOR
Intervention: Surgical control
Number of subjects: 254
Study: 3046300

Group type: EXPERIMENTAL
Intervention: Glucose loading (100 g glucose) in non-pregnant women
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Glucose loading (100 g glucose) in early-pregnant women
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Glucose loading (100 g glucose) in late-pregnant women
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pregnancy progression
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pregnancy (late-pregnant women)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pregnancy (early-pregnant women)
Number of subjects: 50
Study: 31833849

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 725

Group type: COMPARATOR
Intervention: Control (D/C plus emtricitabine/tenofovir-disoproxil-fumarate)
Number of subjects: 725
Study: 31002213

Group type: EXPERIMENTAL
Intervention: Underweight group
Number of subjects: 1310

Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 1310

Group type: COMPARATOR
Intervention: All BMI groups
Number of subjects: 1310
Study: 28388892

Group type: EXPERIMENTAL
Intervention: Exercise-training-group (n=35) received 20-weeks of specific neck/shoulder training.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Reference-group (n=34) received no training.
Number of subjects: 69
Study: 25868634

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 955

Group type: COMPARATOR
Intervention: Fujinon Intelligent Color Enhancement (FICE)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI) for polyps <5 mm
Number of subjects: 955

Group type: COMPARATOR
Intervention: Fujinon Intelligent Color Enhancement (FICE) for polyps <5 mm
Number of subjects: 955
Study: 23861241

Group type: EXPERIMENTAL
Intervention: 12-week endurance exercise program (EG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 21
Study: 21566549

Group type: EXPERIMENTAL
Intervention: CST+OS (conventional standard therapy combined with oral supplementation) for 4 months
Number of subjects: 172

Group type: COMPARATOR
Intervention: CST (conventional standard therapy alone)
Number of subjects: 172
Study: 19943706

Group type: EXPERIMENTAL
Intervention: Sorafenib, a multi‐tyrosine kinase inhibitor, approved as first‐line therapy in HCC.
Number of subjects: 0
Study: 16290015

Group type: EXPERIMENTAL
Intervention: Baseline deficiency of protein C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Baseline deficiency of protein S
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Baseline deficiency of antithrombin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Baseline D-dimer levels
Number of subjects: 30
Study: 15636308

Group type: EXPERIMENTAL
Intervention: S‐Amlodipine 2.5 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 200
Study: 11376633

Group type: COMPARATOR
Intervention: Gemfibrozil (900 mg once daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cerivastatin (0.4 mg once daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9207349

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 207

Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Foscarnet and Ganciclovir
Number of subjects: 207
Study: 8356857

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 2892544

Group type: EXPERIMENTAL
Intervention: Intravenous administration of famotidine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oral administration of famotidine
Number of subjects: 5
Study: 30777900

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 8 mg/2 mL
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (2 mL of saline)
Number of subjects: 98
Study: 28493369

Group type: EXPERIMENTAL
Intervention: 300 mg secukinumab
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 150 mg secukinumab
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 26265659

Group type: EXPERIMENTAL
Intervention: Colchicine for 5 days
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 24093810

Group type: EXPERIMENTAL
Intervention: Stages of change (contemplation and preparation)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Action and maintenance phases
Number of subjects: 137
Study: 21360360

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (n = 33)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (n = 23)
Number of subjects: 56
Study: 18294484

Group type: EXPERIMENTAL
Intervention: Simvastatin (n = 124; 160 mg total, 40 mg orally every 12 hours starting the evening before and ending the morning after the procedure)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo (n = 123)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 247
Study: 16788386

Group type: EXPERIMENTAL
Intervention: Experimental group (Global Posture Reeducation method)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (conventional exercise regimen)
Number of subjects: 40
Study: 12883898

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 9
Study: 11190646

Group type: EXPERIMENTAL
Intervention: Programmed etappenlavage with the Ethizip
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open dorsoventral interval therapy using the TAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 9083323

Group type: EXPERIMENTAL
Intervention: Norgestimate-ethinyl estradiol (active OC treatment)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 8471696

Group type: EXPERIMENTAL
Intervention: 75 mg brofaromine twice a day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 15 mg phenelzine three times a day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3534966

Group type: EXPERIMENTAL
Intervention: Postoperative total pelvic irradiation (3750 cGy divided into 30 fractions over 12 days, 125 cGy per fraction, three fractions per day)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Postoperative total pelvic irradiation plus misonidazole (MISO) (1 g/m2 orally 2 h before the first daily fraction)
Number of subjects: 116

Group type: COMPARATOR
Intervention: No further treatment (cystectomy alone)
Number of subjects: 116
Study: 29490185

Group type: EXPERIMENTAL
Intervention: Hydrocortisone plus Fludrocortisone
Number of subjects: 1241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1241
Study: 26886261

Group type: EXPERIMENTAL
Intervention: Both structured group‐based behavioral health intervention and interpersonal psychotherapy group sessions
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Single intervention (either structured group‐based behavioral health intervention or interpersonal psychotherapy group sessions)
Number of subjects: 1014

Group type: COMPARATOR
Intervention: No new interventions
Number of subjects: 1014
Study: 24577353

Group type: EXPERIMENTAL
Intervention: Faecal transplant from a healthy donor
Number of subjects: 9
Study: 22534422

Group type: EXPERIMENTAL
Intervention: Mesh reinforcement of pancreatic transection (Seamguard or Peristrips Dry)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No mesh reinforcement
Number of subjects: 100
Study: 20435187

Group type: EXPERIMENTAL
Intervention: ST2 levels measured at randomization and after 24, 48, and 72 hours
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: ST2 levels
Number of subjects: 403
Study: 17704884

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication (NF)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Toupet fundoplication (TF)
Number of subjects: 140
Study: 16335887

Group type: EXPERIMENTAL
Intervention: Controlled release nifedipine (20 mg/day) plus candesartan (8 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Candesartan (12 mg/day) - up-titrated monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled release nifedipine plus candesartan combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Candesartan monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with controlled release nifedipine and low-dose candesartan
Number of subjects: 0
Study: 11910308

Group type: EXPERIMENTAL
Intervention: Losartan titration to 100 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg addition
Number of subjects: 90
Study: 9690108

Group type: EXPERIMENTAL
Intervention: Computer-tailored feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iterative computer-tailored feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: General nutrition information letter (Control)
Number of subjects: 0
Study: 7515862

Group type: EXPERIMENTAL
Intervention: Intensified patient teaching
Number of subjects: 60

Group type: COMPARATOR
Intervention: General patient teaching
Number of subjects: 60
Study: 2573143

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study: 4723266

Group type: EXPERIMENTAL
Intervention: Quinine dihydrochloride (490 mg base) via intravenous infusion every 8 hours for 3 days (1.47 gm base daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enteric‐coated tablets of quinine sulfate (540 mg base) given orally every 8 hours for 3 days (1.62 gm base daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gelatin capsules of quinine sulfate (540 mg base) given orally every 8 hours for 3 days (1.62 gm base daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 12
Study: 30484117

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (400 U injected into the affected upper limb)
Number of subjects: 296
Study: 29224827

Group type: EXPERIMENTAL
Intervention: Humidification using the Fisher & Paykel Healthcare MR880 humidifier
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no humidification)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Humidification
Number of subjects: 39
Study: 26823235

Group type: EXPERIMENTAL
Intervention: Self-performed mechanical plaque control (SPC) at 12 h intervals
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Self-performed mechanical plaque control (SPC) at 24 h intervals
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Self-performed mechanical plaque control (SPC) at 48 h intervals
Number of subjects: 39
Study: 24568224

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Integrated training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 23037875

Group type: EXPERIMENTAL
Intervention: Late administration of surfactant (up to 5 doses) plus prolonged inhaled nitric oxide (iNO)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Inhaled nitric oxide (iNO) alone
Number of subjects: 85
Study: 20335831

Group type: EXPERIMENTAL
Intervention: Everolimus 0.75 mg BID
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg BID
Number of subjects: 100